(1) Rajasekaran K (2) Guan X (3) Tafazzol A (4) Hamidi H (5) Darwish M (6) Yadav M
Rajasekara and Guan et al. showed that CMV pp65 tetramer-aided FACS sorting enriched even rare antigen-specific CD8+ T cells, with minimal impact on the relative clonal distribution of the total CD8+ T cell population, the phenotype distribution in individual TCR clones and their transcriptomes. Longer duration pp65 tetramer-mediated CD8+ T cell activation induced the conventional CD8+ T effector and also identified an antigen-specific response gene signature (ASR) that contained genes associated with antigen recognition and metabolic regulation. The ASR added value in predicting PFS in atezolizumab + chemotherapy-treated patients with NSCLC.
Contributed by Paula Hochman
(1) Rajasekaran K (2) Guan X (3) Tafazzol A (4) Hamidi H (5) Darwish M (6) Yadav M
Rajasekara and Guan et al. showed that CMV pp65 tetramer-aided FACS sorting enriched even rare antigen-specific CD8+ T cells, with minimal impact on the relative clonal distribution of the total CD8+ T cell population, the phenotype distribution in individual TCR clones and their transcriptomes. Longer duration pp65 tetramer-mediated CD8+ T cell activation induced the conventional CD8+ T effector and also identified an antigen-specific response gene signature (ASR) that contained genes associated with antigen recognition and metabolic regulation. The ASR added value in predicting PFS in atezolizumab + chemotherapy-treated patients with NSCLC.
Contributed by Paula Hochman
BACKGROUND: Recent advances in single-cell technologies and an improved understanding of tumor antigens have empowered researchers to investigate tumor antigen-specific CD8+ T cells at the single-cell level. Peptide-MHC I tetramers are often utilized to enrich antigen-specific CD8+ T cells, which however, introduces the undesired risk of altering their clonal distribution or their transcriptional state. This study addresses the feasibility of utilizing tetramers to enrich antigen-specific CD8+ T cells for single-cell analysis. METHODS: HLA-A*02:01-restricted human cytomegalovirus (CMV) pp65 peptide-specific CD8+ T cells were used as a model for analyzing antigen-specific CD8+ T cells. Single-cell RNA sequencing and TCR sequencing were performed to compare the frequency and gene expression profile of pp65-specific TCR clones between tetramer-sorted, unstimulated- and tetramer-stimulated total CD8+ T cells. RESULTS: The relative frequency of pp65-specific TCR clones and their transcriptional profile remained largely unchanged following tetramer-based sorting. In contrast, tetramer-mediated stimulation of CD8+ T cells resulted in significant gene expression changes in pp65-specific CD8+ T cells. An Antigen-Specific Response (ASR) gene signature was derived from tetramer-stimulated pp65-specific CD8+ T cells. The ASR signature had a predictive value and was significantly associated with progression free survival in lung cancer patients treated with anti-PD-L1, anti-VEGF, chemotherapy combination (NCT02366143). The predictive power of the ASR signature was independent of the conventional CD8 effector signature. CONCLUSIONS: Our findings validate the approach of enriching antigen-specific CD8+ T cells through tetramer-aided Fluorescence-Activated Cell Sorting (FACS) sorting for single-cell analysis and also identifies an ASR gene signature that has value in predicting response to cancer immunotherapy.
Author Info: (1) Genentech, 1 DNA way, South San Francisco, CA 94080, USA. Electronic address: rajasek1@gene.com. (2) Genentech, 1 DNA way, South San Francisco, CA 94080, USA. (3) Genentech, 1
Author Info: (1) Genentech, 1 DNA way, South San Francisco, CA 94080, USA. Electronic address: rajasek1@gene.com. (2) Genentech, 1 DNA way, South San Francisco, CA 94080, USA. (3) Genentech, 1 DNA way, South San Francisco, CA 94080, USA. (4) Genentech, 1 DNA way, South San Francisco, CA 94080, USA. (5) Genentech, 1 DNA way, South San Francisco, CA 94080, USA. (6) Genentech, 1 DNA way, South San Francisco, CA 94080, USA. Electronic address: yadavm2@gene.com.
Citation: Transl Oncol 2022 Oct 21 27:101559 Epub10/21/2022